chufangao/CTO huggingface dataset:
Clinical trial NCT05552859: Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
Official title: A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT Trial
Acronym: TRENT
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not related to safety concern.
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-05
Primary completion date: 2023-07-28
Completion date: 2023-08-04
Limitations and caveats: The sponsor made the strategic decision to discontinue the trial due to a significant recruitment delay (ie, the number of randomized participants remained significantly lower \[\<10% than originally planned sample size\]). No safety signals were detected during the trial, and the trial team remained blinded to the data collected for the randomized participants at the time of early discontinuation of the trial.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04021082: CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Official title: CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision to not initiate the trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-11-15
Primary completion date: 2022-12-31
Completion date: 2023-06-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04394143: Effect of AD128 to Treat Obstructive Sleep Apnea
Official title: Effect of AD128 on Obstructive Sleep Apnea Severity: a Randomized, Placebo-controlled, Double-blind, Cross-over Study
Sponsor: Centre Hospitalier Universitaire Vaudois (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-20
Primary completion date: 2021-07-19
Completion date: 2021-07-19
Plan to share individual participant data: NO
IPD sharing description: Individual participant data (IPD) could be transmitted on request after publication to researchers who provide a methodologically sound proposal.
Clinical trial NCT03773744: MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
Official title: A Phase 1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing MAGE-A3 (MG1-MAGEA3) With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Immune Modulating Therapy in Patients With Metastatic Melanoma or Previously Treated Cutaneous Squamous Cell Carcinoma
Acronym: Pelican
Sponsor: Turnstone Biologics, Corp. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: insufficient suitable drug supply
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-15
Primary completion date: 2020-10-30
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04398368: Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
Official title: GEMINI: An Open-Label, Single-Arm, Phase II Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Focus research efforts on other projects.
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-05
Primary completion date: 2023-02-02
Completion date: 2023-02-02
Limitations and caveats: Study target enrollment was anticipated for 90 participants but only 23 participants completed treatment before study was terminated. The study was terminated due to insufficient resources and funding to support continuation of the trial. PI decision to terminate.
Clinical trial NCT02437318: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Official title: A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Acronym: SOLAR-1
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 572.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-23
Primary completion date: 2018-06-12
Completion date: 2023-06-09
Baseline population: The Full analysis set (FAS) comprised of all subjects who were randomized to study treatment (alpelisib plus fulvestrant or matching placebo plus fulvestrant).
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04157036: Evaluation of Methylprednisolone or Ibuprofen on Efficacy of Nerve Blocks With Symptomatic Irreversible Pulpitis
Official title: Comparative Evaluation of Preoperative Methylprednisolone or Ibuprofen on Anesthetic Efficacy of Inferior Alveolar Nerve Blocks in Patients With Symptomatic Irreversible Pulpitis
Sponsor: Walter Reed National Military Medical Center (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: COVID halted recruitment for 2 years. A majority of patients eligible for the study had already taken preoperative analgesics, which disqualified them for the study.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-01
Primary completion date: 2021-09-01
Completion date: 2021-10-06
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to share our data with any other Researchers.
Clinical trial NCT03713320: SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
Official title: SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Acronym: SOLAR
Sponsor: miRagen Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early for business reasons, and not due to concerns regarding safety or lack of efficacy.
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-02
Primary completion date: 2020-10-12
Completion date: 2020-12-01
Limitations and caveats: The study was terminated early for business reasons, and not due to concerns regarding safety or lack of efficacy. Because the study was terminated early, enrollment was ended at 37 participants instead of the initially planned 126 participants, and a planned interim analysis based on these 37 participants was the only analysis performed for the study. The study duration was also shortened from an estimated 36 months to 20 months overall.
Plan to share individual participant data: NO
Clinical trial NCT03493542: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
Official title: A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 766.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-31
Primary completion date: 2019-05-01
Completion date: 2023-10-30
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03546816: Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
Sponsor: Vyne Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 285.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-02
Primary completion date: 2020-01-14
Completion date: 2020-02-14
Clinical trial NCT02725528: Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's
Official title: A Multi-Center, Randomized Controlled Trial Comparing The Clinical Effectiveness and Cost-Effectiveness of Collagenase Injection (Xiaflex) and Palmar Fasciectomy in the Management of Dupuytren's Disease
Acronym: EXTEND
Sponsor: McMaster University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-08
Primary completion date: 2021-12-17
Completion date: 2021-12-17
Baseline population: One participant in the limited palmar fasciectomy (LPF) group dropped out immediately after randomization, before baseline outcomes were measured, thus the size of the LPF group is 13, not 14.
Limitations and caveats: Limitations include small sample size, poor recruitment (due health insurance coverage, treatment preference, and the discontinuation of Xiaflex® in Canada), and poor response rate and outcome data collection due to onset and restriction associated with COVID-19 pandemic.
Plan to share individual participant data: NO
Clinical trial NCT04677855: Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Official title: A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Pellficure Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Decision due to insufficient enrollment
Enrollment: 7.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-30
Primary completion date: 2023-10-23
Completion date: 2023-11-20
Plan to share individual participant data: NO
Clinical trial NCT04132648: Curcumin and Exercise in Chronic Kidney Disease
Official title: Vasoconstrictor Responsiveness in Contracting Muscle of CKD: Influence of Acute Curcumin Supplementation
Sponsor: University of Iowa (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI left the Institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-15
Primary completion date: 2021-11-01
Completion date: 2021-11-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04102501: A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Official title: A Randomized, Double-Blind, Controlled, Phase 2/3 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
Sponsor: Retrotope, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-30
Primary completion date: 2021-08-23
Completion date: 2021-08-23
Clinical trial NCT01553071: Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
Official title: Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Sponsor: South Plains Oncology Consortium (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: drug supply issues during COVID-19
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04429321: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Official title: UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Sponsor: Abramson Cancer Center at Penn Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: failure to accrue
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-26
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Plan to share individual participant data: NO
Clinical trial NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
Official title: GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Sponsor: Galera Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility Analysis
Enrollment: 177.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-07
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Baseline population: Modified Intent to Treat Population that includes all randomized subjects that received at least one dose of GC4711/Placebo
Limitations and caveats: Study was terminated early by the Sponsor based on a futility analysis that was conducted in which the trial met the prespecified early termination rules. The last randomized subject did not complete protocol therapy but was followed for safety for a period of 30 days post the last administration of GC4711/Placebo +SBRT.
Plan to share individual participant data: NO
Clinical trial NCT04819360: Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis
Official title: Injections of Botulinum Toxin a or Anticholinergic Treatment As First Line Therapy to Treat Neurogenic Overactive Bladder in Patients with Multiple Sclerosis
Acronym: SEPTOX
Sponsor: Centre Hospitalier Universitaire Vaudois (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of recruitment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2022-03-09
Completion date: 2024-04-21
Plan to share individual participant data: NO
Clinical trial NCT03639610: PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Official title: A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function
Acronym: BRIDGE
Sponsor: Oncopeptides AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
Enrollment: 35.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-08-28
Primary completion date: 2021-12-22
Completion date: 2021-12-22
Baseline population: Baseline characteristics are shown for the Safety Analysis Set, which is defined as all patients who received at least 1 or partial dose of melflufen or dexamethasone.
Limitations and caveats: Between-group comparisons were not performed in this study due the small number of patients in each cohort, as well as differences with regards to some baseline characteristics.
Plan to share individual participant data: NO
Clinical trial NCT03955471: Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
Official title: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Acronym: MOONSTONE
Sponsor: Tesaro, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study will not resume based on the results of a planned interim analysis that showed futility
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-03
Primary completion date: 2021-08-18
Completion date: 2022-01-12
Plan to share individual participant data: NO
Clinical trial NCT03959852: Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain
Official title: A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department
Sponsor: Mercy Health Ohio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Residency completed.
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-11-18
Primary completion date: 2020-06-05
Completion date: 2020-06-05
Clinical trial NCT04064697: Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
Official title: Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Acronym: CYTOVEDO
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: low of inclusions
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-22
Primary completion date: 2023-11-23
Completion date: 2024-02-08
Plan to share individual participant data: NO
Clinical trial NCT03636373: Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
Official title: Investigator-Initiated, Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The Sponsor has decided to stop funding this study due to lack of enrollment during COVID-19 pandemic and decreased interest in funding investigator initiated studies pertaining to the study drug
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-25
Primary completion date: 2021-08-13
Completion date: 2021-08-13
Limitations and caveats: Early termination leading to small numbers of subjects analyzed;
Plan to share individual participant data: NO
Clinical trial NCT04146363: Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
Official title: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 424.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-09-24
Primary completion date: 2021-06-21
Completion date: 2022-05-03
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03610490: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Official title: Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Efficacy
Enrollment: 60.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-17
Primary completion date: 2024-08-21
Completion date: 2024-08-21
Clinical trial NCT04989816: Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
Official title: A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
Acronym: DG-06
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-20
Primary completion date: 2023-06-16
Completion date: 2024-02-28
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All requests will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . A Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT02706249: Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Official title: A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2020-12-07
Completion date: 2021-06-07
Plan to share individual participant data: NO